TipRanks
Actinogen Medical Limited (DE:3AC)
FRANKFURT:3AC
Germany Market

Actinogen Medical (3AC) Drug Pipeline

0 Followers
Drug Name
Condition
Stage
Status
Study Name
Trial Start Date
Article
Xanamem
Alzheimer Disease, Dementia, Mild, Dementia Moderate
Phase II
Recruiting
Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease
Oct 23, 2023
―
Xanamem™
Major Depressive Disorder, Cognitive Impairment, Mdd
Phase II
Completed
Xanamem® in Adults With Major Depressive Disorder and Impaired Cognition (XanaCIDD)
Oct 17, 2022
―
Xanamem® 5 Mg, Xanamem® 10 Mg
Mild Cognitive Impairment, Alzheimer'S Disease
Phase I/II
Completed
A Double-Blind, Placebo-Controlled, Dose Ranging Study of Xanamem® in Healthy Elderly Volunteers
Jul 17, 2021
―
Xanamem™
Dementia, Alzheimer Type
Phase II
Completed
A Phase II Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to AD (XanADu)
Mar 21, 2016
―
Ue2343
Healthy Volunteers
Phase I
Completed
Phase I MAD, Fed-Fasted, CSF Study of UE2343 in Healthy Subjects
Nov 05, 2015
―

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
    What is a clinical trial?
    A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
      What drugs does Actinogen Medical Limited (3AC) have in its pipeline
      3AC is currently developing the following drugs: Xanamem, Xanamem™, Xanamem® 5 Mg, Xanamem® 10 Mg. These drug candidates are in various stages of clinical development as the company works toward FDA approval.